Leveraging opportunities for treatment/user simplicity (LOTUS) : Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs
© 2024 John Wiley & Sons Ltd..
All-oral, direct-acting antivirals can cure hepatitis C virus (HCV) in almost all infected individuals; yet, many individuals with chronic HCV are not treated, and the incidence of acute HCV is increasing in some countries, including the United States. Strains on healthcare resources during the COVID-19 pandemic negatively impacted the progress toward the World Health Organization goal to eliminate HCV by 2030, especially among persons who inject drugs (PWID). Here, we present a holistic conceptual framework termed LOTUS (Leveraging Opportunities for Treatment/User Simplicity), designed to integrate the current HCV practice landscape and invigorate HCV treatment programs in the setting of endemic COVID-19: (A) treatment as prevention (especially among PWID), (B) recognition that HCV cure may be achieved with variable adherence with evidence supporting some forgiveness for missed doses, (C) treatment of all persons with active HCV infection (viremic), regardless of acuity, (D) minimal monitoring (MinMon) during treatment, and (E) rapid test and treat (TnT). The objective of this article is to review the current literature supporting each LOTUS petal; identify remaining gaps in knowledge or data; define the remaining barriers facing healthcare providers; and review evidence-based strategies for overcoming key barriers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - (2024) vom: 03. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sulkowski, Mark S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Direct-acting antivirals |
|---|
| Anmerkungen: |
Date Revised 04.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/jvh.13927 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369234340 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369234340 | ||
| 003 | DE-627 | ||
| 005 | 20240304233222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.13927 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM369234340 | ||
| 035 | |a (NLM)38433561 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sulkowski, Mark S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Leveraging opportunities for treatment/user simplicity (LOTUS) |b Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 John Wiley & Sons Ltd. | ||
| 520 | |a All-oral, direct-acting antivirals can cure hepatitis C virus (HCV) in almost all infected individuals; yet, many individuals with chronic HCV are not treated, and the incidence of acute HCV is increasing in some countries, including the United States. Strains on healthcare resources during the COVID-19 pandemic negatively impacted the progress toward the World Health Organization goal to eliminate HCV by 2030, especially among persons who inject drugs (PWID). Here, we present a holistic conceptual framework termed LOTUS (Leveraging Opportunities for Treatment/User Simplicity), designed to integrate the current HCV practice landscape and invigorate HCV treatment programs in the setting of endemic COVID-19: (A) treatment as prevention (especially among PWID), (B) recognition that HCV cure may be achieved with variable adherence with evidence supporting some forgiveness for missed doses, (C) treatment of all persons with active HCV infection (viremic), regardless of acuity, (D) minimal monitoring (MinMon) during treatment, and (E) rapid test and treat (TnT). The objective of this article is to review the current literature supporting each LOTUS petal; identify remaining gaps in knowledge or data; define the remaining barriers facing healthcare providers; and review evidence-based strategies for overcoming key barriers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a direct-acting antivirals | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a persons who inject drugs (PWID) | |
| 700 | 1 | |a Martinez, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Tyson, Gia L |e verfasserin |4 aut | |
| 700 | 1 | |a Scholz, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Ricardo A |e verfasserin |4 aut | |
| 700 | 1 | |a Kohli, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Julius, Susan F |e verfasserin |4 aut | |
| 700 | 1 | |a Deming, Paulina |e verfasserin |4 aut | |
| 700 | 1 | |a Fink, Scott A |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Keisa |e verfasserin |4 aut | |
| 700 | 1 | |a Roytman, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Stainbrook, Tuesdae R |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Marshe D |e verfasserin |4 aut | |
| 700 | 1 | |a Viera-Briggs, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Ramers, Christian B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g (2024) vom: 03. März |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:03 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.13927 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 03 |c 03 | ||